This bill introduces new safety and procedural requirements for clinician-administered drugs by amending the Managed Care Law (RSA 420-J). It defines "clinician-administered drug" as an outpatient prescription drug that cannot be reasonably self-administered and is typically administered by a healthcare professional in a clinical setting. The bill prohibits health insurers and pharmacy benefit managers (PBMs) from mandating that these drugs be dispensed through specific arrangements, such as "white bagging" or "brown bagging," without prior written consent from both the provider and the patient. Additionally, it ensures that enrollees retain the right to choose their provider or pharmacy for obtaining these drugs without facing additional fees or restrictions.

The bill also includes provisions that prevent health carriers and PBMs from interfering with the enrollee's choice of provider, limiting coverage based on the dispensing pharmacy, or imposing higher costs for clinician-administered drugs not dispensed by a selected pharmacy. The effective date for these changes is set for January 1, 2027. Overall, the bill aims to enhance patient safety and care while ensuring that patients have the freedom to choose how they receive their medications.